FDA
-
-
-
-
-
-
-
Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2021 Financial Results
-
-
-
-
-
-
-
Kronos Bio Inc. (KRON) Announces FDA Clearance of Investigational New Drug Application for Lanraplenib (LANRA) for Treatment of Patients with Acute Myeloid Leukemia
-
-
-
-
-
-
-
Kronos Bio Inc. (KRON) Announces Positive End-of-Phase 2 Meeting with FDA for Entospletinib in Newly Diagnosed NPM1-mutated Acute Myeloid Leukemia
-
-
-
-
-
322,882 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

